Pharmaceutical

AFM-24I by Affimed for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

AFM-24I is under clinical development by Affimed and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC).

Feb 8, 2024 - 18:00
AFM-24I is under clinical development by Affimed and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC).
Read the original article

Tags:

Previous Article

INCB-57643 by Incyte for Myelofibrosis: Likelihood of Approval

Next Article

(Edetate disodium + ethyl alcohol + minocycline hydrochloride) by Citius Pharmac...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

NMPA approves Astellas’ PADCEV for advanced urothelial cancer

NMPA approves Astellas’ PADCEV for advanced urothelial ...

Aug 21, 2024

Avoid “narrow national interest” in fighting next pandemic, WHO chief says

Avoid “narrow national interest” in fighting next pande...

Jan 17, 2024

STAT+: Novartis reportedly decides to pass on Cytokinetics

STAT+: Novartis reportedly decides to pass on Cytokinetics

Jan 16, 2024